Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice.
Qingjuan ZuoGuorui ZhangLili HeSai MaHuijuan MaJianlong ZhaiZhongli WangTingting ZhangYan WangYifang GuoPublished in: Drug design, development and therapy (2022)
Canagliflozin may attenuate hepatic steatosis by improving lipid metabolism, enhancing autophagy, and reducing inflammatory response through ASS1/AMPK pathway. Besides, canagliflozin further effectively improves the aortic endothelial function, thereby suppressing atherosclerosis development.
Keyphrases
- inflammatory response
- cardiovascular disease
- signaling pathway
- cell death
- aortic valve
- physical activity
- cognitive decline
- lipopolysaccharide induced
- oxidative stress
- endoplasmic reticulum stress
- south africa
- high fat diet
- left ventricular
- toll like receptor
- fatty acid
- heart failure
- type diabetes
- protein kinase
- metabolic syndrome